Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Cogstate Ltd ( (AU:CGS) ) is now available.
Cogstate Ltd announced a correction to a previously released Change in Director’s Interest Notice for CEO Bradley O’Connor, rectifying a typographical error in the number of securities held. The corrected notice reflects an accurate total of 5,338,929 securities. This amendment ensures transparency and accuracy in the company’s disclosures, maintaining trust with stakeholders and compliance with ASX regulations.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd is a neuroscience technology company focused on optimizing brain health assessments to aid in the development of new medicines and provide earlier clinical insights in healthcare. The company offers computerized cognitive tests and electronic clinical outcome assessment solutions, supporting biopharmaceutical companies, academic institutions, and healthcare providers globally. Cogstate has partnered with Eisai to distribute its assessments in the USA and Asia.
YTD Price Performance: 74.16%
Average Trading Volume: 99,076
Technical Sentiment Signal: Buy
Current Market Cap: A$309M
For a thorough assessment of CGS stock, go to TipRanks’ Stock Analysis page.